September 11th 2025
Discover groundbreaking research on hard-to-treat skin conditions like hidradenitis suppurativa and vitiligo at the EADV 2025 Congress in Paris.
New AAD Acne Guidelines Warn About High Cost, Access to New Treatments
February 6th 2024New acne guidelines from the American Academy of Dermatology recommend Winlevi (clascoterone), a topical treatment, and Seysara (sarecycline), a narrow-spectrum tetracycline, but qualify the recommendation as conditional because of concerns that the high cost may affect equitable access to treatment,
Read More
Study Examines the Correlation Between COVID-19 Vaccination and Vitiligo Onset
January 24th 2024A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.
Read More
Vtama Is Getting Ready to Elbow Its Way Into the Crowded Field of Atopic Dermatitis Medications
January 19th 2024The FDA approved Dermavant Science's Vtama (tapinarof cream) last year as a treatment for plaque psoriasis. Sales have been disappointing, according to press reports. Will Vtama, which has a different mechanism of action than the current batch of topical medications for atopic dermatitis, fare better in the atopic dermatitis market?
Read More
The similarity of symptoms means children already diagnosed with atopic dermatitis may not receive patch testing for allergic contact dermatitis, resulting in underdiagnosis of the comorbidity, say the authors of a study published in the Journal of the American Academy of Dermatology.
Read More
Reduced Mortality Associated With Vitiligo
October 2nd 2023In a population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about risks of mortality among these patients. The researchers investigated all-cause and cause-specific mortality of patients with vitiligo compared with controls without vitiligo using a nationwide database.
Read More
Can Cognitive Behavioral Therapy Change Quality of Life for AD Patients?
September 26th 2023Cognitive behavioral therapy with exposure treatment might help but few people with AD receive any form of behavioral intervention, say Dorian Kern and colleagues from Karolinska Institutet, Stockholm.
Read More
Scripius Removes Dupixent from Formulary
September 7th 2023The decision by Scripius (previously Select Health Prescriptions) was made based on the cost of Dupixent, as well as because of an increased demand to use Dupixent for mild atopic dermatitis when the primary patient population is those with moderate to severe disease.
Read More